225 related articles for article (PubMed ID: 12732206)
1. ULBP4 is a novel ligand for human NKG2D.
Chalupny NJ; Sutherland CL; Lawrence WA; Rein-Weston A; Cosman D
Biochem Biophys Res Commun; 2003 May; 305(1):129-35. PubMed ID: 12732206
[TBL] [Abstract][Full Text] [Related]
2. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor.
Cosman D; Müllberg J; Sutherland CL; Chin W; Armitage R; Fanslow W; Kubin M; Chalupny NJ
Immunity; 2001 Feb; 14(2):123-33. PubMed ID: 11239445
[TBL] [Abstract][Full Text] [Related]
3. The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions.
Sutherland CL; Chalupny NJ; Cosman D
Immunol Rev; 2001 Jun; 181():185-92. PubMed ID: 11513139
[TBL] [Abstract][Full Text] [Related]
4. Four novel ULBP splice variants are ligands for human NKG2D.
Cao W; Xi X; Wang Z; Dong L; Hao Z; Cui L; Ma C; He W
Int Immunol; 2008 Aug; 20(8):981-91. PubMed ID: 18544572
[TBL] [Abstract][Full Text] [Related]
5. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells.
Sutherland CL; Chalupny NJ; Schooley K; VandenBos T; Kubin M; Cosman D
J Immunol; 2002 Jan; 168(2):671-9. PubMed ID: 11777960
[TBL] [Abstract][Full Text] [Related]
6. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein.
Rölle A; Mousavi-Jazi M; Eriksson M; Odeberg J; Söderberg-Nauclér C; Cosman D; Kärre K; Cerboni C
J Immunol; 2003 Jul; 171(2):902-8. PubMed ID: 12847260
[TBL] [Abstract][Full Text] [Related]
7. Conformational plasticity revealed by the cocrystal structure of NKG2D and its class I MHC-like ligand ULBP3.
Radaev S; Rostro B; Brooks AG; Colonna M; Sun PD
Immunity; 2001 Dec; 15(6):1039-49. PubMed ID: 11754823
[TBL] [Abstract][Full Text] [Related]
8. The NKG2D ligand ULBP4 binds to TCRgamma9/delta2 and induces cytotoxicity to tumor cells through both TCRgammadelta and NKG2D.
Kong Y; Cao W; Xi X; Ma C; Cui L; He W
Blood; 2009 Jul; 114(2):310-7. PubMed ID: 19436053
[TBL] [Abstract][Full Text] [Related]
9. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity.
Dunn C; Chalupny NJ; Sutherland CL; Dosch S; Sivakumar PV; Johnson DC; Cosman D
J Exp Med; 2003 Jun; 197(11):1427-39. PubMed ID: 12782710
[TBL] [Abstract][Full Text] [Related]
10. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Song H; Kim J; Cosman D; Choi I
Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
[TBL] [Abstract][Full Text] [Related]
11. Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D.
Bacon L; Eagle RA; Meyer M; Easom N; Young NT; Trowsdale J
J Immunol; 2004 Jul; 173(2):1078-84. PubMed ID: 15240696
[TBL] [Abstract][Full Text] [Related]
12. ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15.
Sutherland CL; Rabinovich B; Chalupny NJ; Brawand P; Miller R; Cosman D
Blood; 2006 Aug; 108(4):1313-9. PubMed ID: 16621962
[TBL] [Abstract][Full Text] [Related]
13. RAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity.
Cao W; Xi X; Hao Z; Li W; Kong Y; Cui L; Ma C; Ba D; He W
J Biol Chem; 2007 Jun; 282(26):18922-8. PubMed ID: 17470428
[TBL] [Abstract][Full Text] [Related]
14. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
Raffaghello L; Prigione I; Airoldi I; Camoriano M; Levreri I; Gambini C; Pende D; Steinle A; Ferrone S; Pistoia V
Neoplasia; 2004; 6(5):558-68. PubMed ID: 15548365
[TBL] [Abstract][Full Text] [Related]
15. UL16 binding proteins.
Cao W; He W
Immunobiology; 2004; 209(3):283-90. PubMed ID: 15518340
[TBL] [Abstract][Full Text] [Related]
16. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
[TBL] [Abstract][Full Text] [Related]
17. Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D.
Eleme K; Taner SB; Onfelt B; Collinson LM; McCann FE; Chalupny NJ; Cosman D; Hopkins C; Magee AI; Davis DM
J Exp Med; 2004 Apr; 199(7):1005-10. PubMed ID: 15051759
[TBL] [Abstract][Full Text] [Related]
18. Cutting an NKG2D Ligand Short: Cellular Processing of the Peculiar Human NKG2D Ligand ULBP4.
Zöller T; Wittenbrink M; Hoffmeister M; Steinle A
Front Immunol; 2018; 9():620. PubMed ID: 29651291
[TBL] [Abstract][Full Text] [Related]
19. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.
Carbone E; Neri P; Mesuraca M; Fulciniti MT; Otsuki T; Pende D; Groh V; Spies T; Pollio G; Cosman D; Catalano L; Tassone P; Rotoli B; Venuta S
Blood; 2005 Jan; 105(1):251-8. PubMed ID: 15328155
[TBL] [Abstract][Full Text] [Related]
20. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice.
Cerwenka A; Bakker AB; McClanahan T; Wagner J; Wu J; Phillips JH; Lanier LL
Immunity; 2000 Jun; 12(6):721-7. PubMed ID: 10894171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
